FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Portfolio Pulse from
Alnylam Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) to the FDA for the expanded use of Amvuttra to treat ATTR amyloidosis with cardiomyopathy. This could potentially broaden the drug's market and increase revenue for the company.
November 26, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals has submitted an sNDA to the FDA for Amvuttra, aiming to expand its use to treat ATTR amyloidosis with cardiomyopathy. This could lead to increased market share and revenue if approved.
The submission of an sNDA for Amvuttra indicates a potential expansion of its market, which could lead to increased sales and revenue for Alnylam. The FDA's review is a critical step, and approval would likely have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100